Castle Biosciences vs Fulgent Genetics
Castle Biosciences and Fulgent Genetics are similar in size: $344m and $323m of revenue in their latest fiscal years. Fulgent Genetics grew faster (13.8% against 3.7%). Castle Biosciences kept more of each dollar of sales as profit: a net margin of -7.0% against -18.8%. Fulgent Genetics carries less debt relative to equity (0.2% against 2.2%).
| Latest fiscal year | Castle BiosciencesCSTL, 2025 | Fulgent GeneticsFLGT, 2025 |
|---|---|---|
| Revenue | $344m | $323m |
| Revenue growth | 3.7% | 13.8% |
| Net income | −$24.2m | −$60.5m |
| Operating margin | -12.4% | -28.2% |
| Net margin | -7.0% | -18.8% |
| Return on equity | -5.2% | -5.4% |
| Free cash flow | $28.3m | −$124m |
| Cash | $117m | $50.2m |
| Total debt | $10.2m | $2.4m |
| Debt to equity | 2.2% | 0.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $10.9m |
| Employees | 883 | — |
| Market value | $1.07bn | $531m |
| Price vs our value range | — | — |
| Moat score | 32 (Weak) | 23 (Weak) |
| Insider trades, 12 months | 0 buys, 170 sales | 0 buys, 15 sales |